A randomized, placebo-controlled, and observer-blinded Phase IIb, multi-center clinical study of BPZE1 versus Boostrix
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs BPZE 1 (Primary) ; DTaP vaccine
- Indications Pertussis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors ILiAD Biotechnologies
- 19 Nov 2019 According to an ILiAD Biotechnologies media release, Cheryl Keech, M.D., Ph.D played an a pivotal role in advising the company and designing of this study.
- 08 Oct 2019 According to an ILiAD Biotechnologies media release, results from this study are expected at the end of Q1 2020.
- 08 Oct 2019 Status changed from recruiting to active, no longer recruiting, according to an ILiAD Biotechnologies media release.